Skip to main content

Table 4 Association between hippocampus dose and neurocognitive test deterioration

From: Hippocampus-sparing radiotherapy using volumetric modulated arc therapy (VMAT) to the primary brain tumor: the result of dosimetric study and neurocognitive function assessment

 

Mean dose (EQD2/2)

 

Bilateral hippocampi

P value

Right hippocampus

P value

Left hippocampus

P value

SVLT-Total recall

 

0.033a

 

0.398

 

0.013a

 No Deterioration (n = 23)

10.6 ± 6.5

 

15.7 ± 16.8

 

11.8 ± 14.1

 

 Deterioration (n = 3)

20.3 ± 11.5

 

7.2 ± 1.7

 

37.7 ± 27.6

 

SVLT-Delayed recall

 

0.115

 

0.558

 

0.074

 No Deterioration (n = 24)

11.0 ± 6.7

 

15.2 ± 16.6

 

13.1 ± 15.0

 

 Deterioration (n = 2)

19.8 ± 16.3

 

8.2 ± 0.1

 

36.0 ± 38.9

 

SVLT-Recognition

 

0.003a

 

0.427

 

0.001a

 No Deterioration (n = 23)

10.2 ± 6.0

 

13.8 ± 15.8

 

11.1 ± 11.7

 

 Deterioration (n = 3)

23.3 ± 9.4

 

21.8 ± 19.5

 

43.1 ± 30.9

 

RCFT-COPY

 

0.469

 

0.211

 

0.261

 No Deterioration (n = 20)

11.1 ± 6.6

 

16.9 ± 17.7

 

12.7 ± 14.9

 

 Deterioration (n = 6)

13.7 ± 10.7

 

7.5 ± 3.7

 

22.0 ± 24.6

 

RCFT-Immediate recall

 

0.156

 

0.513

 

0.081

 No Deterioration (n = 24)

11.1 ± 6.6

 

15.3 ± 16.5

 

13.1 ± 15.0

 

 Deterioration (n = 2)

19.0 ± 17.4

 

7.4 ± 1.2

 

36.0 ± 39.4

 

RCFT-Delayed recall

 

0.156

 

0.513

 

0.081

 No Deterioration (n = 24)

11.1 ± 6.6

 

15.3 ± 16.5

 

13.1 ± 15.0

 

 Deterioration (n = 2)

19.0 ± 17.4

 

7.4 ± 1.2

 

35.6 ± 39.4

 

RCFT-Recognition

 

0.042a

 

0.406

 

0.257

 No Deterioration (n = 23)

10.6 ± 6.5

 

13.8 ± 16.0

 

13.4 ± 15.2

 

 Deterioration (n = 3)

19.9 ± 11.5

 

22.1 ± 20.9

 

25.8 ± 32.7

 
  1. Numbers are represented as mean ± SD
  2. SVLT Seoul Verbal Learning Test, RCFT Rey Complex Figure Test and Recognition Trial
  3. aindicate statistical significance by student’s t-test
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us